Abstract
The possible pathogenic role of triglycerides (TG) in the development of ischemic stroke is still under extensive investigation. Recently, apolipoprotein (apo)A5 gene promoter region T-1131C polymorphism has been shown to associate with elevated serum TG levels. In the current work, a total of 302 subjects were classified as being large vessel-associated, small vessel-associated, or belonging to a mixed group of ischemic stroke-affected patients. The level of TG was increased in all groups (p<0.01). The apoA5-1131C allele frequency was approximately twofold in all groups of stroke patients compared with the controls (5 vs 10–12%; p<0.05); and the apoA5-1131C allele itself was also found to associate with increased TG levels in all groups. In a multivariate logistic regression analysis model adjusted for differences in age, gender, serum cholesterol, hypertension, pressence of diabetes mellitus, smoking and drinking habits, and ischemic heart disease, a significantly increased risk of developing stroke disease was found in patients carrying the apoA5-1131C allele (p<0.05; odds ratio OR=2.1 [1.3–4.7]); this association was also proven for all subtypes of the stroke. The results presented here suggest that the apoA5-1131C allele is an independent risk factor for the development of stroke. Being that apoA5 gene is under the control of the peroxisome proliferator-activated receptor α, theoretically, the current observations also can have long-term therapeutic consequences.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abney M., McPeek M. S., and Ober C. (2001) Broad and narrow heritabilities of quantitative traits in a founder population. Am. J. Hum. Genet. 68, 1302–1307.
Beckstead J. A., Oda M. N., Martin D. D., et al. (2003) Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry 42, 9416–9423.
Bi N., Yan S.K., Li G.P., Yin Z. N., and Chen B. S. (2004) A single nucleotide polymorphism-1131T>C in the apoliporotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol. Genet. Metab. 83, 280–286.
Bravata D. M., Wells C. K., Kernan W. N., Concato J., Brass L. M., and Gulanski B. I. (2005) Association between impaired insulin sensitivity and stroke, Neuroepidemiology 25, 69–74.
Elbaz A. and Amarenco P. (1999) Genetic susceptibility and ischaemic stroke. Curr. Opin. Neurol. 12, 47–55.
Endo K., Yanagi H., Araki J., Hirano C., Yamakawa-Kobayashi K., and Tomura S. (2002) Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum. Genet. 111, 570–572.
Fruchart-Najib J., Bauge E., Niculescu L. S., et al. (2004) Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 319, 397–404.
Hachinski V., Graffagnino C., Beaudry M., et al. (1996) Lipids and stroke: a paradox resolved. Arch. Neurol. 53, 303–308.
Haheim L. L., Holme I., Hjermann I., and Leren P. (1993) Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. Stroke 24, 1484–1489.
Hassan A. and Markus H. S. (2000) Genetics and ischaemic stroke. Brain 123(Pt 9), 1784–1812.
Heller D. A., de Faire U. Pedersen N. L., Dahlen G., and McClearn G. E. (1993) Genetic and environmental influences on serum lipid levels in twins. N. Engl. J. Med. 328, 1150–1156.
Lai C. Q., Demissie S., Cupples L. A., et al. (2004) Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J. Lipid Res. 45, 2096–2105.
Lindenstrom E., Boysen G., and Nyboe J. (1994) Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 309, 11–15.
Merkel M. and Heeren J. (205) Give me A5 for lipoprotein hydrolysis. J. Clin. Invest. 115, 2694–2696.
Merkel M., Loeffler B., Kluger M., et al. (2005) Apolipoprotein AV accelerates plasma hydrolysis of trilgy ceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280, 21,553–21,560.
Nabika T., Nasreen S., Kobayashi S., and Masuda J., (2002) The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 165, 201–204.
Olofsson S. O. (2005) apoA-V; the regulation of a regulator of plasma triglycerides. Arterioscler. Thromb. Vasc. Biol. 25, 1097–1099.
Pedro-Botet J., Senti M., Nogues X., et al. (2001) Lipoprotein and apolipoprotein profile in men with ischemic stoke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Btroke 23, 1556–1562.
Pennacchio L. A., Olivier M., Hubacek J. A., et al. (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294, 169–173.
Pennacchio L. A., Olivier M., Hubacek J. A., Krauss R. M., Rubin E. M. and Cohen J. C. (2002) Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11, 3031–3038.
Prieur X., Coste H., and Rodriguez J. C. (2003) The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J. Biol. Chem. 278, 25,468–25,480.
Rhoads G. G. and Feinleib M. (1983) Serum triglyceride and risk of coronary heart disease, stroke and total mortality in Japanese-American men. Arteriosclerosis 3, 316–322.
Rothwell P. M., Coull A. J., Silver L. E., et al. (2005) Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vaslcular Study). Lancet 366, 1773–1783.
Ruiz-Narvaez E. A., Yang Y., Nakanish Y., Kirchdorfer J., and Campos H. (2005) APOCA3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J. Lipid Res. 46, 2605–2613.
Salas J., Jansen S., Lopez-Miranda J., et al. (1998) The SstI polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats. Am. J. Clin. Nutr. 68, 396–401.
Salonen J. T., Puska P., Tuomilehto J., and Homan K. (1982) Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. A longitudinal study in Eastern Finland. Stroke 13, 327–333.
Schaap F. G., Rensen P. C., Voshol P. J., et al. (2004) ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279, 27,941–27,947.
Simons L. A., McCallum J., Freidlander Y., and Simons J. (1998) Risk factors for ischemic stroke: Dubbo Study of the elderly. Stroke 29, 1341–1346.
Stump C. S., Clark S. E., and Sowers J. R. (2005) Oxidative stress in insulin-resistant conditions: cardiovascular implications. Treat. Endocrinol. 4, 343–351.
Szalai C., Keszei M., Duba J., et al. (2004) Polymorphism in the promoter region of the apoliprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 173, 109–114
Szolnoki Z., Havasi V., Talian G., et al., (2005) Lymphotoxin-alpha gene 252G allelic variant is a risk factor for large-vessel-associated ischemic stroke. J. Mol. Neurosci. 27, 205–211.
Szolnoki Z., Somogyvari F., Kondacs A., et al. (2003) Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. J. Neurol Neurosurg. Psychiatry 74, 1615–1620.
Talmud P.J., Hawe E., Martin S., et al. (2002) Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11, 3039–3046.
Vu-Dac N., Gervois P., Jakel H., et al. (2003) Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J. Biol. Chem. 278, 17,982–17,985.
Waterworth D. M., Hubacek J. A., Phitha J., et al. (2000) Plasma levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI-APOE cluster. J. Lipid Res. 41, 1103–1109.
Weinberg R. B., Cook V. R., Beckstead J. A., et al. (2003) Structure and interfacial properties of human apolipoprotein A-V. J. Biol. Chem. 278, 34,438–34,444.
WHO Study Group (1985) Diabetes mellitus. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 727, 1–113.
Yan, S. K., Cheng X. Q., Song Y. H., Xiao X. H., Bi N., and Chen B. S. (2005) Apolipoprotein A5 gene polymor phism-1131T→C: association with plasma lipids and type 2 diabetes mellitus with coronary heart disease in Chinese. Clin. Chem. Lab. Med. 43, 607–612.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Havasi, V., Szolnoki, Z., Talián, G. et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 29, 177–183 (2006). https://doi.org/10.1385/JMN:29:2:177
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/JMN:29:2:177